-
Mashup Score: 5Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease | Pfizer - 16 day(s) ago
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated and demonstrated an immune response non-inferior to adults aged 60 years and older Pfizer intends to submit these findings to regulatory agencies to seek approval of ABRYSVO in adults 18 to 59 years of age Pfizer Inc. (NYSE: PFE) today announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial ( NCT05842967 ) MONeT (RSV I M munizati ON Study for Adul T s at Higher Risk of Severe Illness), evaluating a single dose of ABRYSVO versus placebo in adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD). Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD 1,2 . Among US adults 18 to 49 years of age, 9.5 percent have a
Source: www.pfizer.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1Investigational RSV Maternal Vaccine: Was Efficacious, But Showed Increase for Preterm Birth - 22 day(s) ago
The RSV prefusion F protein–based maternal vaccine phase 3 trial was halted due to the risk of this adverse event.
Source: www.contagionlive.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 1Respiratory Syncytial Virus (RSV) Vaccination in Older Adults - 27 day(s) ago
Impact of the RSVPreF3 vaccine on respiratory illness in older adults in the US.
Source: www.contagionlive.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 1Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages - 1 month(s) ago
Nature Communications – Here the authors describe a stabilization technology that engineers crosslinks between tyrosine sidechains into a natively folded vaccine immunogen and show that…
Source: www.nature.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 10Study details why phase 3 trial of GSK's RSV vaccine for pregnant women was halted early - 1 month(s) ago
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 10Study details why phase 3 trial of GSK's RSV vaccine for pregnant women was halted early - 1 month(s) ago
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 3CDC Monitoring Rare Neurologic Events After RSV Vaccination - 1 month(s) ago
Cases of Guillain-Barre syndrome in vaccinated older adults slightly higher than background rates
Source: www.medpagetoday.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 145RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC - 2 month(s) ago
Beyfortus, a new shot for RSV, was 90% effective at preventing hospitalizations in children, new data shows.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 143RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC - 2 month(s) ago
Beyfortus, a new shot for RSV, was 90% effective at preventing hospitalizations in children, new data shows.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 112Early Estimate of Nirsevimab Effectiveness for Prevention ... - 2 month(s) ago
This report describes effectiveness of nirsevimab against respiratory syncytial virus-associated hospitalizations in infants.
Source: www.cdc.govCategories: General Medicine News, General NewsTweet
Today, we announced positive top-line data from the Phase 3 study of our respiratory syncytial virus (#RSV) vaccine in adults ages 18-59 with an increased risk for the disease. Learn more: https://t.co/hZVrhurwXa https://t.co/BREsWKMsCk